Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag. (Funded by Novartis; VAYHIT2 ClinicalTrials.gov number, NCT05653219.).
Publications
4 shownAmerican Society of Hematology 2019 guidelines for immune thrombocytopenia
Abstract Background: Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials...
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower m...
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Abstract Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This a...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 4
- Citations
- 3,227
- Institution
- Hammersmith Hospital
External Links
Identifiers
- ORCID
- 0000-0002-9845-8292
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.